Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Discovering Glioblastoma: From Diagnosis to Treatment
share announcement

Discovering Glioblastoma: From Diagnosis to Treatment

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Causes, Screening and Diagnosis".

Deadline for manuscript submissions: closed (15 February 2023) | Viewed by 12574

Special Issue Editors

Prof. Dr. Giuseppe Lombardi

E-Mail Website
Guest Editor
Department of Oncology, Oncology 1, Veneto Institute of Oncology-IRCCS, 35128 Padua, Italy
Interests: neuro-oncology; glioblastoma; gliomas; targeted therapy; brain tumors; immunotherapy; quality of life
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Marta Scorsetti

E-Mail Website
Guest Editor
1. Radiotherapy and Radiosurgery Department, IRCCS Humanitas Research Hospital, Milan, Italy
2. Department of Biomedical Sciences, Humanitas University, Milan, Italy
Interests: radiotherapy; radiosurgery; glioblastoma; neuro-oncology; glioma; targeted therapy; clinical and translational research in neuro-oncology
Prof. Dr. Francois Ducray

E-Mail Website
Guest Editor
Department of Neuro-Oncology, Hospices Civils de Lyon, Bron, France
Interests: gliomas; glioblastoma stem cells; targeted therapies; tumor heterogeneity
Special Issues, Collections and Topics in MDPI journals
Dr. Evangelia D. Razis

E-Mail Website
Guest Editor
Medical Oncology 3, Hygeia Hospital, Athens, Greece
Interests: glioblastoma; neuro-oncology; targeted therapy; translational research; breast cancer brain metastases

Special Issue Information

Dear Colleagues,

Glioblastoma represents the most frequent and aggressive malignant primary brain tumor in adults. Despite growing knowledge of the molecular changes responsible for tumor development, glioblastoma remains a neoplasm with unmet medical needs and its prognosis still remains poor. Median overall survival of glioblastoma patients is about 15 months; only 3–5% of patients are alive after five years from diagnosis and, theoretically, all patients relapse. Therefore, it appears to be very important to characterize the tumor both at diagnosis and at recurrence with advanced imaging, such as MR spectroscopy and positron emission tomography, and analyze molecular alterations.

It is noteworthy that molecular alterations could represent important prognostic factors and specific targets for precision medicine trials in primary and recurrent glioblastoma. In the last few years, many translational and clinical studies have been performed, and new treatments with targeted therapy such as precision medicine, immunotherapy and their combination are ongoing.

This Special Issue will cover all aspects of glioblastoma, including original research on advanced imaging, molecular characteristics, current and experimental treatment options, supportive care, neurocognitive functions, and quality of life. Expert opinions, systematic reviews, and meta-analyses are also welcome.

Prof. Dr. Giuseppe Lombardi
Prof. Dr. Marta Scorsetti
Prof. Dr. Francois Ducray
Dr. Evangelia D. Razis
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • glioblastoma
  • immunotherapy
  • targeted therapy
  • immunotherapy
  • personalized medicine
  • glioma

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (5 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

15 pages, 3461 KiB  
Article
Reticulocalbin 3 Is a Novel Mediator of Glioblastoma Progression
by Yi He, Salvador Alejo, Jessica D. Johnson, Sridharan Jayamohan and Gangadhara R. Sareddy
Cancers 2023, 15(7), 2008; https://doi.org/10.3390/cancers15072008 - 28 Mar 2023
Viewed by 2229
Abstract
Glioblastoma is the most common malignant primary brain tumor. Molecular mechanisms underlying the pathobiology of glioblastoma are incompletely understood, emphasizing an unmet need for the identification of new therapeutic candidates. Reticulocalbin 3 (RCN3), an ER lumen-residing Ca2+ binding protein, plays an essential [...] Read more.
Glioblastoma is the most common malignant primary brain tumor. Molecular mechanisms underlying the pathobiology of glioblastoma are incompletely understood, emphasizing an unmet need for the identification of new therapeutic candidates. Reticulocalbin 3 (RCN3), an ER lumen-residing Ca2+ binding protein, plays an essential role in protein biosynthesis processes via the secretory pathway. Emerging studies demonstrated that RCN3 is a target for therapeutic intervention in various diseases. However, a knowledge gap exists about whether RCN3 plays a role in glioblastoma. Publicly available datasets suggest RCN3 is overexpressed in glioblastoma and portends poor survival rates. The knockdown or knockout of RCN3 using shRNA or CRISPR/Cas9 gRNA, respectively, significantly reduced proliferation, neurosphere formation, and self-renewal of GSCs. The RNA-seq studies showed downregulation of genes related to translation, ribosome, and cytokine signaling and upregulation of genes related to immune response, stem cell differentiation, and extracellular matrix (ECM) in RCN3 knockdown cells. Mechanistic studies using qRT-PCR showed decreased expression of ribosomal and increased expression of ER stress genes. Further, in silico analysis of glioblastoma patient datasets showed RCN3 expression correlated with the ribosome, ECM, and immune response pathway genes. Importantly, the knockdown of RCN3 using shRNA significantly enhanced the survival of tumor-bearing mice in orthotopic glioblastoma models. Our study suggests that RCN3 could be a potential target for the development of a therapeutic intervention in glioblastoma. Full article
(This article belongs to the Special Issue Discovering Glioblastoma: From Diagnosis to Treatment)
►▼ Show Figures

Figure 1

15 pages, 2003 KiB  
Article
Far-Red Fluorescent Murine Glioma Model for Accurate Assessment of Brain Tumor Progression
by Tatiana A. Mishchenko, Irina V. Balalaeva, Maria O. Klimenko, Anna A. Brilkina, Nina N. Peskova, Evgenii L. Guryev, Dmitri V. Krysko and Maria V. Vedunova
Cancers 2022, 14(15), 3822; https://doi.org/10.3390/cancers14153822 - 6 Aug 2022
Cited by 3 | Viewed by 2414
Abstract
Glioma is the most common brain tumor, for which no significant improvement in life expectancy and quality of life is yet possible. The creation of stable fluorescent glioma cell lines is a promising tool for in-depth studies of the molecular mechanisms of glioma [...] Read more.
Glioma is the most common brain tumor, for which no significant improvement in life expectancy and quality of life is yet possible. The creation of stable fluorescent glioma cell lines is a promising tool for in-depth studies of the molecular mechanisms of glioma initialization and pathogenesis, as well as for the development of new anti-cancer strategies. Herein, a new fluorescent glioma GL261-kat cell line stably expressing a far-red fluorescent protein (TurboFP635; Katushka) was generated and characterized, and then validated in a mouse orthotopic glioma model. By using epi-fluorescence imaging, we detect the fluorescent glioma GL261-kat cells in mice starting from day 14 after the inoculation of glioma cells, and the fluorescence signal intensity increases as the glioma progresses. Tumor growth is confirmed by magnetic resonance imaging and histology. A gradual development of neurological deficit and behavioral alterations in mice is observed during glioma progression. In conclusion, our results demonstrate the significance and feasibility of using the novel glioma GL261-kat cell line as a model of glioma biology, which can be used to study the initialization of glioma and monitor its growth by lifetime non-invasive tracking of glioma cells, with the prospect of monitoring the response to anti-cancer therapy. Full article
(This article belongs to the Special Issue Discovering Glioblastoma: From Diagnosis to Treatment)
►▼ Show Figures

Figure 1

13 pages, 995 KiB  
Article
Definition of the Prognostic Role of MGMT Promoter Methylation Value by Pyrosequencing in Newly Diagnosed IDH Wild-Type Glioblastoma Patients Treated with Radiochemotherapy: A Large Multicenter Study
by Mario Caccese, Matteo Simonelli, Veronica Villani, Simona Rizzato, Tamara Ius, Francesco Pasqualetti, Marco Russo, Roberta Rudà, Rosina Amoroso, Luisa Bellu, Roberta Bertorelle, Francesco Cavallin, Angelo Dipasquale, Mariantonia Carosi, Stefano Pizzolitto, Daniela Cesselli, Pasquale Persico, Beatrice Casini, Matteo Fassan, Vittorina Zagonel and Giuseppe Lombardiadd Show full author list remove Hide full author list
Cancers 2022, 14(10), 2425; https://doi.org/10.3390/cancers14102425 - 13 May 2022
Cited by 8 | Viewed by 2619
Abstract
Background. O6-methylguanine (O6-MeG)-DNA methyltransferase (MGMT) methylation status is a predictive factor for alkylating treatment efficacy in glioblastoma patients, but its prognostic role is still unclear. We performed a large, multicenter study to evaluate the association between MGMT methylation value [...] Read more.
Background. O6-methylguanine (O6-MeG)-DNA methyltransferase (MGMT) methylation status is a predictive factor for alkylating treatment efficacy in glioblastoma patients, but its prognostic role is still unclear. We performed a large, multicenter study to evaluate the association between MGMT methylation value and survival. Methods. We evaluated glioblastoma patients with an assessment of MGMT methylation status by pyrosequencing from nine Italian centers. The inclusion criteria were histological diagnosis of IDH wild-type glioblastoma, Eastern Cooperative Oncology Group Performance Status (ECOG-PS) ≤2, and radio-chemotherapy treatment with temozolomide. The relationship between OS and MGMT was investigated with a time-dependent Receiver Operating Characteristics (ROC) curve and Cox regression models. Results. In total, 591 newly diagnosed glioblastoma patients were analyzed. The median OS was 16.2 months. The ROC analysis suggested a cut-off of 15% for MGMT methylation. The 2-year Overall Survival (OS) was 18.3% and 51.8% for MGMT methylation <15% and ≥15% (p < 0.0001). In the multivariable analysis, MGMT methylation <15% was associated with impaired survival (p < 0.00001). However, we also found a non-linear association between MGMT methylation and OS (p = 0.002): median OS was 14.8 months for MGMT in 0–4%, 18.9 months for MGMT in 4–40%, and 29.9 months for MGMT in 40–100%. Conclusions. Our findings suggested a non-linear relationship between OS and MGMT promoter methylation, which implies a varying magnitude of prognostic effect across values of MGMT promoter methylation by pyrosequencing in newly diagnosed IDH wild-type glioblastoma patients treated with chemoradiotherapy. Full article
(This article belongs to the Special Issue Discovering Glioblastoma: From Diagnosis to Treatment)
►▼ Show Figures

Figure 1

15 pages, 1847 KiB  
Article
Impact of Levetiracetam Treatment on 5-Aminolevulinic Acid Fluorescence Expression in IDH1 Wild-Type Glioblastoma
by Johannes Wach, Ági Güresir, Motaz Hamed, Hartmut Vatter, Ulrich Herrlinger and Erdem Güresir
Cancers 2022, 14(9), 2134; https://doi.org/10.3390/cancers14092134 - 25 Apr 2022
Cited by 2 | Viewed by 1889
Abstract
The amino acid 5-aminolevulinic acid (5-ALA) is the most established neurosurgical fluorescent dye and facilitates the achievement of gross total resection. In vitro studies raised concerns that antiepileptic drugs (AED) reduce the quality of fluorescence. Between 2013 and 2018, 175 IDH1 wild-type glioblastoma [...] Read more.
The amino acid 5-aminolevulinic acid (5-ALA) is the most established neurosurgical fluorescent dye and facilitates the achievement of gross total resection. In vitro studies raised concerns that antiepileptic drugs (AED) reduce the quality of fluorescence. Between 2013 and 2018, 175 IDH1 wild-type glioblastoma (GB) patients underwent 5-ALA guided surgery. Patients’ data were retrospectively reviewed regarding demographics, comorbidities, medications, tumor morphology, neuropathological characteristics, and their association with intraoperative 5-ALA fluorescence. The fluorescence of 5-ALA was graded in a three point scaling system (grade 0 = no; grade 1 = weak; grade 2 = strong). Univariable analysis shows that the intake of dexamethasone or levetiracetam, and larger preoperative tumor area significantly reduce the intraoperative fluorescence activity (fluorescence grade: 0 + 1). Multivariable binary logistic regression analysis demonstrates the preoperative intake of levetiracetam (adjusted odds ratio: 12.05, 95% confidence interval: 3.91–37.16, p = 0.001) as the only independent and significant risk factor for reduced fluorescence quality. Preoperative levetiracetam intake significantly reduced intraoperative fluorescence. The indication for levetiracetam in suspected GB should be carefully reviewed and prophylactic treatment avoided for this tumor entity. Future comparative trials of neurosurgical fluorescent dyes need a special focus on the influence of levetiracetam on fluorescence intensity. Further trials must validate our findings. Full article
(This article belongs to the Special Issue Discovering Glioblastoma: From Diagnosis to Treatment)
►▼ Show Figures

Graphical abstract

Review

Jump to: Research

26 pages, 2407 KiB  
Review
Metabolomic and Lipidomic Profiling of Gliomas—A New Direction in Personalized Therapies
by Magdalena Gaca-Tabaszewska, Joanna Bogusiewicz and Barbara Bojko
Cancers 2022, 14(20), 5041; https://doi.org/10.3390/cancers14205041 - 14 Oct 2022
Cited by 8 | Viewed by 2124
Abstract
In addition to being the most common primary brain tumor, gliomas are also among the most difficult to diagnose and treat. At present, the “gold standard” in glioma treatment entails the surgical resection of the largest possible portion of the tumor, followed by [...] Read more.
In addition to being the most common primary brain tumor, gliomas are also among the most difficult to diagnose and treat. At present, the “gold standard” in glioma treatment entails the surgical resection of the largest possible portion of the tumor, followed by temozolomide therapy and radiation. However, this approach does not always yield the desired results. Additionally, the ability to cross the blood-brain barrier remains a major challenge for new potential drugs. Thus, researchers continue to search for targeted therapies that can be individualized based on the specific characteristics of each case. Metabolic and lipidomic research may represent two of the best ways to achieve this goal, as they enable detailed insights into the changes in the profile of small molecules in a biological system/specimen. This article reviews the new approaches to glioma therapy based on the analysis of alterations to biochemical pathways, and it provides an overview of the clinical results that may support personalized therapies in the future. Full article
(This article belongs to the Special Issue Discovering Glioblastoma: From Diagnosis to Treatment)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-5
Back to TopTop